Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has started recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to potentially eliminate the need for corrective eyewear.
The Group Two study will evaluate both safety and vision performance, including near and distance vision, in patients receiving the latest-generation Ocumetics Lens implanted with an enhanced delivery system. This marks a departure from Group One, which focused solely on safety, and represents a critical phase in the clinical development of the technology.
According to Dean Burns, President and CEO of Ocumetics, the commencement of Group Two is an important milestone. "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens," Burns said. "Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
The company also highlighted that Group One patients are reaching their 12-month follow-up visits, which will provide longer-term clinical data. The positive outcomes from Group One, which met and exceeded expectations regarding safety, performance, and handling, have paved the way for this next stage.
The Ocumetics Lens is designed to fit within the natural lens compartment of the eye and use the eye's natural muscle activity to shift focus from distance to near, potentially providing clear vision at all distances without glasses or contact lenses. The Group Two study will use the company's enhanced delivery system, reflecting continued technological evolution.
Burns emphasized the significance of the 12-month milestone and the introduction of next-generation technology: "We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens. At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system."
The Mexico City clinical facility, which successfully performed Group One surgeries in Fall 2025, is now identifying and recruiting eligible patients for the upcoming Fall 2026 surgeries. The company expects recruitment to be completed soon, with surgical dates to be scheduled thereafter.
These developments are crucial for Ocumetics as it progresses through the clinical trial phases required for regulatory approval and eventual commercialization. The company is currently in the first-in-human early feasibility study phase, and the data from Group Two will be instrumental in demonstrating the lens's efficacy and safety in a broader patient population.
For more information about Ocumetics and its technology, interested parties can visit the company's website or follow its updates on social media. The company's shares are traded on the TSX Venture Exchange under the symbol OTC, on the OTCQB under OTCFF, and on the Frankfurt Stock Exchange under 2QBO.
This announcement underscores Ocumetics' commitment to developing advanced vision correction solutions that enhance the quality of life for patients, potentially transforming the field of ophthalmology.
